.

Simon Tomlinson - Chief Executive Officer, Board Member and Co-Founder

Simon is Chief Executive Officer, a member of the Board of Directors and a co-founder of Akriveia Therapeutics.

Prior to co-founding Akriveia with Ulrich Rodeck and John Williams he operated a life-science strategy and transaction advisory firm, Velocity Partners, which he founded in 2008 serving biotechnology, pharmaceutical and pharmaceutical services companies. Until 2008 Simon was Senior Vice President of Business Development at publicly traded Pharmacopeia Inc., a high-throughput drug discovery company acquired by Ligand Pharmaceuticals. Pharmacopeia had previously acquired Molecular Simulations Inc. where Simon was Vice President of Global Pharma Partnering and General Manager of the company’s European subsidiary in Munich. Simon joined industry from academia as a scientist and programmer at computer-aided molecular design company Biosym Technologies Inc., which was ultimately acquired by Molecular Simulations. He holds a BSc in Chemistry from University College London and a Ph.D. in the field of Computational Chemistry, also from UCL.